Every few weeks, a peptide seller opens a letter from the FDA.
Most of them never saw it coming.
PeptAIOS
The AI operating system for peptide businesses.
Small peptide sellers run on guesswork
- Under about 20 staff, no compliance person, and rules spread across FDA, FTC, DOJ and the states.
- A storefront that makes claims it should not, and nobody checking.
- Customer records in three places, and no clean link from batch to order.
- A market full of confident myths, repeated by the generic AI tools they already pay for.
A compliance tool that repeats the myths is worse than no tool at all.
What missing a change costs
Source: PeptAIOS PRD, enforcement record, October 2026. An indictment is an allegation, not a conviction; everyone charged is presumed innocent unless proven guilty.
Take an AI operating system that already runs real businesses,
and make it speak peptide.
Compliance Watch
- Reads seven US federal sources on a schedule: FDA warning letters, FDA Category 2, FDA criminal investigations, the Federal Register, eCFR, FTC and DOJ.
- Reports only what is new, matched to the substances and terms each seller cares about.
- Weekly or daily digest, and an instant alert when a watched substance is named.
- Now runs as a hosted service: one monitor serving many subscribers, every issue read and approved by a person before it goes out.
Quiet when nothing changed. Loud when something broke.
It does not cry wolf
- Everything already published is recorded on day one, not reported as new.
- If a government page changes shape, the source is flagged as degraded instead of reporting every row as removed.
Source: Compliance Watch live run, 3 October 2026.
The page mentions BPC-157. The list does not.
- FDA's Category 2 page has two tables: substances in Category 2, and substances whose nominations were withdrawn.
- BPC-157 sits in the withdrawn table. A tool that searches the page reports it as Category 2. That is wrong.
- Compliance Watch reads the right table and the category column, and keeps the two apart.
- Removal from Category 2 alone does not mean a substance may be compounded or sold.
Source: FDA Category 2 bulk drug substances page, as read 3 October 2026.
Presence is not status.
Bring back the customers who went quiet
- Reads Shopify or WooCommerce orders and finds customers who are due to reorder, bought once, or lapsed.
- Drafts the message for each, with product suggestions it can explain.
- Holds back a test group, so the report shows the lift, not just the sends.
- A simple review page on the seller's own machine: read, edit, approve or reject every draft.
Nothing goes out that would embarrass the seller
- Blocks disease and treatment claims, dosing language, drug comparisons and safety promises.
- Adds the research-use-only line, an unsubscribe link and the business address to every email.
- Hides products the seller has restricted in a customer's state.
- Respects a daily send cap and quiet hours. Sending needs a typed confirmation for that exact batch.
The tool drafts. A person approves. Nothing sends by accident.
Everything a small seller needs, in one place
- Customer records, Mission Control dashboard, bookkeeping, contract review and a second brain built from their own documents.
- Runs inside the AI assistant they already use. Their data stays on their machine.
Source: PeptAIOS 2.0 release, 5 October 2026.
Built, tested and released
- PeptAIOS 2.0 released on 5 October 2026 to its own private repository.
- Compliance Watch 2.1: 107 automated tests. Win-back 1.1: 182 automated tests.
- Two full clean installs passed, every module checked, before release.
- A one-command release process, so a fix ships to every customer within a week.
Source: PeptAIOS release check, 5 October 2026.
Regulatory news, not legal advice
- Not legal, regulatory or medical advice, and no attorney-client relationship.
- US federal sources only for now. State boards and a second country come next.
- Can miss or delay items. It depends on what agencies publish. The coverage statement says where the gaps are.
- No licensed attorney has signed off yet. The wording is a reviewed draft, waiting for that sign-off before paid live sends.
Five things we decide together
- The name. Keep PeptAIOS, or choose from the shortlist with free domains.
- The attorney. Who reviews the Compliance Watch wording, and when.
- The price model. Flat subscription, or a fee with a results guarantee, or one for each product.
- The partner terms. Written down before anyone sells.
- The first pilot. Which seller, which storefront, and what success looks like in 90 days.
Which seller do we start with?
What would make this a yes for you?